(INNS)
UBAMATAMAB(INND)
UBAMATAMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA, ANTI-[HOMO SAPIENS MUC16 (MUCIN 16, MUC-16, CANCER ANTIGEN 125, CA125)] AND ANTI-[HOMO SAPIENS CD3E (CD3E, CD3 EPSILON)], MONOCLONAL ANTIBODY, BISPECIFIC; GAMMA4 HEAVY CHAIN ANTI-MUC16 (1-443) [VH ANTI-MUC16 (HOMO SAPIENS IGHV3-11*01 (88.8%) -(IGHD) -IGHJ5*01 (100%), CDRIMGT [8.8.10] (26-33.51-58.97-106)) (1-117)-HOMO SAPIENS IGHG4*01, G4V5 H P10 (CH1 (118-215), HINGE 1-12 S10>P (225) (215-227), CH2 E1.4,F1.3>P1.3 (230), L1.2>V (231), G1.1>A (232) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131- 215')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-215') [V-KAPPA (HOMO SAPIENS IGKV1-39*01 (97.9%) -IGKJ5*01 (100%), CDR-IMGT [6.3.10] (27-32.50-52.89-98)) (1'-108') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (154), V101 (192) (109'-215')];...; PROPOSED INN: LIST 125, RECOMMENDED INN: LIST 87(WHO)
UBAMATAMABUM(INN)